

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**




Figure 1: Schematic of the particle laden lens inserted in the eye




Figure 2: Particle size distribution for Type 1 (Canola oil/Water microemulsion stabilized by Tween 80 and Panadon SDK) microemulsion




Figure 3: Figure 2: Particle size distribution for Type 2 (Canola oil/Water microemulsion stabilized by Tween 80 and Panadon SDK and a silica shell) microemulsion




Figure 4: Particle size distribution for Type 3 (Hexadecane/ Water microemulsion stabilized by Brij 97) microemulsion




Figure 5: Particle size distribution for Type 4 (Hexadecane/ Water microemulsion stabilized by Brij 97 and a silica shell) microemulsion




Figure 6: Transmittance values of different hydrogels




Figure 7: Comparison of long term release rates from hydrogels prepared by: **a)** directly dissolving Lidocaine in polymerization mixture; **b)** dissolving Lidocaine molecules in the oil phase of Type 4 microemulsion with 3% oil




Figure 8: Comparison of short term release rates from hydrogels prepared by: **a)** directly dissolving Lidocaine in polymerization mixture; **b)** dissolving Lidocaine molecules in the oil phase of Type 4 microemulsion




Figure 9: Drug diffusion from hydrogels loaded with Type 2 and Type 4 microemulsions. Both hydrogels contain the same drug concentration of 0.22 mg Lidocaine (oil soluble form)/gr of hydrogel.




Figure 10: Drug release from a Type 3 hydrogel loaded with (a) 0.42 mg (b) 0.3 mg (c) 0.17 mg lidocaine (oil soluble form)/gr hydrogel




Figure 11: Drug release by liposome laden contact lens




Figure 12: SEM image of a pure p-HEMA hydrogel




Figure 13: SEM image of a hydrogel loaded with drug-laden particles of Type 1 microemulsion




Figure 14: SEM image of a hydrogel loaded with drug-laden particles of Type 2 microemulsion




Figure 15: SEM image of a hydrogel loaded with drug-laden particles of Type 3 microemulsion




Figure 16: SEM image of a hydrogel loaded with drug-laden particles of Type 4 microemulsion




Figure 17: SEM image of a hydrogel loaded with drug-laden particles of Type1 microemulsion at a higher magnification showing the particles




Figure 18: SEM image of a hydrogel loaded with drug-laden particles of Type 2 microemulsion at a higher magnification showing the particles




Figure 19: SEM image of a hydrogel loaded with drug-laden particles of Type 4 microemulsion at a higher magnification showing the particles